Objective:To study the clinical effect of Zhenqi Fuzheng capsules, clindamycin combined with low-dose compound sulfamethoxazole in the treatment of non-HIV-infected pneumocystis pneumonia (NH-PCP). Methods:Nity-three cases of NH-PCP treated in our hospital were randomly divided into the control group (n=46) and the combined medication group (n=47).The control group was treated with conventional-dose compound sulfamethoxazole and the combined medication group was treated with Zhenqi Fuzheng capsules,clindamycin and low-dose compound sulfamethoxazole.Blood routine indexes,blood oxygen indexes, related serum biomarkers and immune function indexes were detected and compared between the two groups before and after treatment. The clinical efficacy and the adverse reactions of the two groups was compared. Results:The levels of lymphocyte count (LYM)and albumin (ALB) in the blood routine indexes, blood oxygen indexes,related serum biomarkers and immune function indexes in the combined medication group were significantly better than those in the control group (P<0.05).The total effective rate of the combined medication group was significantly higher that of the control group (91.49% vs.76.09%,χ2=4.077,P=0.043).The incidence of adverse reactions in the combined medication group was significantly lower than that of the control group (P<0.05). Conclusions:Zhenqi Fuzheng capsules,clindamycin combined with low-dose compound sulfamethoxazole in the treatment of NH-PCP can significantly improve the clinical efficacy,promote LYM,ALB and blood oxygen indexes,improve related serum biomarkers and immune function.It is safe and worthy of clinical application.
 BIENVENU A L,TRAORE K,PLEKHANOVA I,et al.Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J].Int J Infect Dis,2016,46:11-17.
 TASAKA S,TOKUDA H.Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies[J].J Infect Chemother,2012,18(6):793-806.
 CHANG H M,TSAI H C,LEE S S,et al.High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS[J].J Chin Med Assoc,2016,79(6):314-319.
 LI H,HUANG H,HE H.Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin:a case report and literature review[J].BMC Pulm Med,2016,16(1):144.
 LI M C,LEE N Y,LEE C C,et al.Pneumocystis jiroveci pneumonia in immunocompromised patients:Delayed diagnosis and poor outcomes in non-HIV-infected individuals[J].J Microbiol Immunol Infect,2014,47(1):42-47.
 NAKASHIMA K,AOSHIMA M,NAKASHITA T,et al.Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunocompromised patients:A single-center retrospective observational cohort study[J].J Microbiol Immunol Infect,2017:in press.
 SALERNO D,MUSHATT D,MYERS L,et al.Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients[J].Respir Med,2014,108(11):1688-1695.
 LI Y,GHANNOUM M,DENG C,et al.Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases:Usefulness of lymphocyte subtyping[J].Int J Infect Dis,2017,57:108-115.